Locke Lord advised MindImmune Therapeutics, Inc. on the deal. MindImmune Therapeutics Inc., a drug discovery company pioneering a new approach to treat Alzheimer’s disease and other...
MindImmune Therapeutics’ Issuance and Sale of $12.4 Million Series A Convertible Preferred Stock
Integer’s $220 Million million Acquisition of Oscor
Gleiss Lutz advised Integer on the deal while Locke Lord represented Oscor. The US company Integer, a leading medical device outsource manufacturer, announced its USD 220...